Compare · DRIO vs RMD
DRIO vs RMD
Side-by-side comparison of DarioHealth Corp. (DRIO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRIO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 509.5x DRIO ($55.0M).
- Over the past year, DRIO is down 47.9% and RMD is down 23.1% - RMD leads by 24.8 points.
- RMD has been more active in the news (6 items in the past 4 weeks vs 2 for DRIO).
- RMD has more recent analyst coverage (25 ratings vs 4 for DRIO).
- Company
- DarioHealth Corp.
- ResMed Inc.
- Price
- $7.50+5.04%
- $193.21-1.43%
- Market cap
- $55.0M
- $28.02B
- 1M return
- +0.60%
- -6.57%
- 1Y return
- -47.92%
- -23.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 6
- Recent ratings
- 4
- 25
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DRIO
- Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
- Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
- DarioHealth Reports First Quarter 2026 Financial and Operating Results
- SEC Form 10-Q filed by DarioHealth Corp.
- SEC Form SD filed by DarioHealth Corp.
- DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
- Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
- SEC Form 3 filed by new insider Palumbo John R
- DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.